Vera Therapeutics, Inc.

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

The pharmaceutical, biotech and other allied industries came together in London on 4 December to celebrate another year of exceptional achievement at the 20th Annual Scrip Awards at the Raffles hotel

Two and a half months after its first US Food and Drug Administration approval for Incyte Corp.-partnered Niktimvo (axatilimab-csfr) in chronic graft-versus-host disease (GVHD), Syndax Pharmaceuticals

RemeGen Ltd. has clinched a major Phase III clinical win for its BlyS/APRIL dual targeting fusion protein telitacicept, the Chinese firm’s backbone asset in the autoimmune disease area, in Chinese pa